India's largest drug maker Sun Pharmaceutical on Thursday posted a decline of 19 per cent year-on-year (Y-o-Y) for its consolidated net profit for the fourth quarter of the financial year 2025 (Q4FY25) at Rs 2,149.8 crore. Meanwhile, its revenue from operations rose by 8 per cent at Rs 12,958.8 crore.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
'There is need for India-specific pricing.' 'Google, Microsoft and others also have different pricing.' 'It is important for OpenAI to think on these lines as the global pricing may not work in the Indian context.'
'There has been a spurt of algo platforms, and algo developers, which are neither empaneled nor regulated, but are still active in the ecosystem.'
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
Isn't there something significant in the UPI example for all of us to learn from and execute to enable world-scale success for our startups?, asks Ajit Balakrishnan.
'The world over, everybody is asking for the same medicines, same APIs, same KSMs.' 'However, there is just one supplier -- China -- for the entire world.'
Many enter this arena without a detailed understanding of how their algo works.' 'Diligently review information on the strategy, risk profile, potential losses, and expected gains before investing.'
Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.
At 6.15 pm, when the van reached the base of Mumbra Devi temple on Mumbra bypass, Akshay suddenly tried to pull out API More's pistol, the complaint said.
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
'Growth for some companies has been hard to come by and this is a smart way to get there.'
A magistrate's inquiry has found five policemen responsible for the custodial death of Akshay Shinde, who was accused in the Badlapur school sexual assault case. The Bombay High Court ordered an FIR to be registered against the five policemen, following the magistrate's report. Shinde was arrested in August 2024 for allegedly assaulting two minor girls and was killed in an alleged police shootout in September while being taken from prison for questioning. The police claimed he snatched a gun and opened fire, but the magistrate found the five officers responsible for his death. The court has asked the public prosecutor to inform the bench in two weeks on which probe agency will investigate the case.
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.
The outage raised broader concerns about the dependency on a few large tech companies controlling critical platforms.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
An official said Akshay Shinde, who worked as a cleaner at the school, was being taken to Badlapur from Taloja jail for investigation.
Developers in India now have expanded access to Google's powerful AI models with the 2 million token context window in Gemini 1.5 Pro and Gemma 2, the next generation of open models.
A team of forensic science experts on Tuesday examined the police vehicle, in which Shinde was allegedly shot by a cop on Monday evening, they said. Shinde, 24, was accused of sexually assaulting two minor girls at a school in Badlapur town of Thane district.
'It has remained around 38 per cent over the past four to five quarters.'
'A long-term investor with a 4 to 5 year horizon could invest in this theme via SIPs.'
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
The family members of Badlapur sexual assault case accused Akshay Shinde have challenged the police claim that he fired at a policeman first following which cops fired in self-defence which led to his death.
The average cost of data breaches in India reached $2.18 million in 2023, marking a 28 per cent increase since 2020, according to the Reserve Bank of India's (RBI) Currency and Finance report for 2023-24. The report said that India's average data breach cost was still below the global average. The most common attacks in India are phishing which was at 22 per cent and stolen or compromised credentials was 16 per cent. The automotive industry is highly vulnerable to cyber attacks, whereas the banking and financial services sector, benefiting from stringent regulations, enjoys comparatively stronger protection.
'Digital courts will alleviate congestion in traditional courts.'
The Reserve Bank of India (RBI) will launch the Unified Lending Interface (ULI) nationwide in due course, aiming to transform India's lending sector, similar to how the Unified Payments Interface (UPI) revolutionised the payments ecosystem, Governor Shaktikanta Das said on Monday.
It is being suggested that apps, such as WhatsApp and Telegram, should share their APIs with each other to ensure there is interoperability, just as it exists across email services.
'There is not any negative connotation associated with it.'
While asserting that the CoWIN portal is completely safe with adequate safeguards for data privacy, it said an internal exercise has been initiated to review the existing security measures of CoWIN.
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.
Google unveiled on Wednesday a slate of artificial intelligence (AI) tools and technologies for Indian developers at its first I/O Connect event for India, being held in Bengaluru. The company made accessible for Indian developers its faster, more accurate large language AI model accessible through PaLM API, Makersuite, as well as features on Google Cloud's Vertex AI. Google Cloud officially launched a new initiative in collaboration with Open Network for Digital Commerce (ONDC), under the Department for Promotion of Industry and Internal Trade, to help sellers build and scale commerce platforms across the country.
'A credit line on UPI is going to make banks think about credit fundamentally as they digitise the credit process entirely.'
'We celebrated our little Dua's birthday yesterday... the sweetest and the smiliest baby who lights up our home with laughter and pure love.'
Nirma's tryst with the pharmaceutical space started in 2006 when it acquired the ailing Core Healthcare in a deal reported to be worth Rs 300 crore. The Ahmedabad-based manufacturer of intravenous fluids was subsequently renamed Nirlife. Pharma industry insiders say Nirma, which broke open the detergent market in the 1990s with low prices and massive advertising, tried an encore of the low-price strategy in pharma, but with mixed results.
'The stockbroker should have a good balance sheet to support its scale of operations. It should also have proper risk management in terms of margins so that it doesn't go bankrupt during extreme market movements.' 'The broker must have a track record of navigating several market cycles in an ethical and transparent manner.'
A man from Bihar was arrested and a juvenile was apprehended in connection with their involvement in the alleged data leak from CoWIN portal, officials said on Thursday.
Living up to name: Beed's Little Sachin Dhas lives his father's dream
The pharmaceutical and the consumer durables sectors, which depend on China for imports, have not been impacted yet due to unrest in China with people protesting against lockdowns. But the lockdown could have an impact on the supply of components used in consumer durables if it continues for the next fortnight. In the pharmaceutical industry, Indian players import 66-70 per cent of their bulk drug requirements from China.
The central government has for the first time allowed a private company, Bajaj Healthcare, to process opium to extract alkaloids used to make pain-killers, cough syrups, and even cancer drugs. Two government factories in Ghazipur, Uttar Pradesh, and Neemuch, Madhya Pradesh, do the work yet, processing some 800 tonnes of opium gum annually to extract alkaloids. The government on Tuesday gave Thane-based Bajaj Healthcare an initial contract to process 500 tonnes of opium gum annually and wants production to be at 800 tonnes per annum (tpa) in the next five years, indicating the state's exit from the highly-regulated sector.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances